IONS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ionis Pharmaceuticals Inc (IONS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive news catalysts, and hedge fund buying trends outweigh the short-term technical weakness and mixed financial performance. The FDA Priority Review for olezarsen and a catalyst-rich 2026 make this a compelling long-term opportunity.
The MACD is negatively expanding (-0.344), and RSI is neutral at 35.083. Moving averages are converging, indicating no strong trend. The stock is trading near its pivot level (82.258), with key resistance at 84.76 and support at 79.756. Overall, the technical indicators suggest a neutral to slightly bearish short-term trend.
FDA Priority Review for olezarsen with a target date of June 30,
Strong analyst ratings with multiple price target increases (e.g., Needham raised to $103, Wells Fargo to $100).
Hedge funds are significantly increasing their holdings (+242.57%).
Revenue growth of 34% YoY in 2025 driven by strong product sales and R&D collaborations.
Q4 revenue declined by 10.41% YoY to $203 million.
Adjusted loss of $1.15 for Q4, although better than Wall Street estimates.
Gross margin dropped by 2.29% YoY to 96.06%.
Short-term technical indicators are neutral to slightly bearish.
In Q4 2025, revenue dropped 10.41% YoY to $203 million, while net income improved significantly to -$229 million (+119.46% YoY). EPS increased to -$1.41 (+113.64% YoY). Gross margin declined slightly to 96.06% (-2.29% YoY). Despite mixed results, the company shows potential for long-term growth driven by its product pipeline and R&D collaborations.
Analysts are overwhelmingly positive on IONS, with multiple firms raising price targets recently (e.g., Needham to $103, Wells Fargo to $100, Barclays to $95). Analysts highlight a catalyst-rich 2026, strong fundamentals, and favorable risk/reward dynamics.
